Open Orphan Share Discussion Threads

[m5] 02/12/2020 08:42

Not 100% sure to be honest but I am sure the water will clear.

I have totally the opposite experience Little Minx, the man is on the money I would say 75% of the time. You take as you find.

Anyway we know what coming down the line, just timings.

"The unblinding of the results normally would not be of big relevance to ORPH but unless it leads to something else which Doc is strongly hinting at.He has had a big steer from CF imo as he is not a pharma guy".

[judijudi] 02/12/2020 08:41

m5,
Oh right
I see

[little minx] 02/12/2020 08:35

So what is Doc up to? Bit pointless putting up comments which mean nothing. In fact Doc involved normally makes me sell up and move on so I hope this time it is something good.

[toyin] 02/12/2020 08:31

m5, I certainly hope not!

[judijudi] 02/12/2020 08:15

m5,
Who’s Doc please?

[m5] 02/12/2020 08:11

Doc is at the OO facility at the moment. Something must be brewing. Imho.

[holdbucket] 02/12/2020 07:36

Yes, I spotted that as did Jeansey 8817 "Whopping great 710k trade reported late. Interesting"

[molatovkid] 02/12/2020 06:06

I'm sure there was a 710K trade the other day that I posted about.

[troutisout] 01/12/2020 23:35

free stock charts from uk.advfn.com

[pogue] 01/12/2020 23:14

CF has told us already that the trial is being done in December is that what the Doc is hinting or am I missing the clues?

[m5] 01/12/2020 22:31

Courtesy of the Doc...........


#ORPH I draw your attention to RNS 28th July and encourage you splice the data together...

More tomorrow folks Syringe

#CovidVaccine #COVIDー19





Open Orphan PLC Contract for COVID-19 Vaccine Trial
28/07/2020 7:00am
UK Regulatory (RNS & others)

Open Orphan (LSE:ORPH)
Historical Stock Chart

From Jun 2020 to Dec 2020

Click Here for more Open Orphan Charts.
TIDMORPH

RNS Number : 2256U

Open Orphan PLC

28 July 2020

28 July 2020

Open Orphan plc

("Open Orphan" or the "Company")

Awarded Contract from Codagenix Inc. New York USA for COVID-19 Vaccine Trial

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce a new contract with Codagenix Inc. ("Codagenix") to conduct a first in human (Phase I) trial evaluating safety and immunogenicity of a single-dose, intranasal SARS-CoV-2 (COVID-19) vaccine candidate in 48 healthy young adult volunteers.

Highlights:

-- First in human (Phase I) study of CodaVax-COVID, a codon deoptimized SARS-CoV-2 (COVID-19) single-dose, intranasal vaccine candidate

-- Vaccine being trialled at hVIVO's state-of-the-art Quarantine Facility in Whitechapel in London

-- Phase I study to start in early Autumn with initial data expected by the end of 2020
-- Study will include second dose as surrogate viral challenge at Day 28
hVIVO, part of Open Orphan, will conduct the COVID-19 vaccine trial for Codagenix at its state-of-the-art Quarantine Facility. CodaVax-COVID is a live-attenuated vaccine that replicates very slowly, but contains all SARS-CoV-2 proteins, unlike most other vaccines that only contain the viral spike. This vaccine has the potential to induce broad antibody, cellular and mucosal immunity with a single intranasal dose. hVIVO is currently kicking off the initial steps of this exciting study and are expected to start the trial in the quarantine unit this autumn.

This contract reinforces Open Orphan's position as the world leader in the testing of vaccines and antivirals.

Cathal Friel, Executive Chairman, Open Orphan, said:

"We are proud to be conducting this Phase I study for Codagenix, a leader in their field, as it will help bring a promising vaccine candidate to the public to help combat the COVID-19 pandemic as quickly as possible.

hVIVO, with its unique quarantine facility, is one of the few organisations in the world that has now publicly stated that it is working on testing COVID-19 vaccines for efficacy using human challenge model clinical trials.

Today's announcement also shows that hVIVO's quarantine facility is uniquely suited to conducting Phase I studies for infectious disease vaccines such as this.

Codagenix's expertise in viral design technology, combined with hVIVO's Phase I trial capability, gives us confidence that this trial will be successful and a step forward for the world as it seeks to develop a COVID-19 vaccine to bring the pandemic to a close."

Sybil Tasker, MD, MPH, Chief Medical Officer of Codagenix, said:

"We are very excited to be collaborating with hVIVO for the first-in-human study of CodaVax-COVID. hVIVO is world-recognized for expertise in evaluation of live viruses in human volunteers. Based on our animal data we expect this vaccine to be effective with a single dose, but will also evaluate a repeat dose to assess potential for boosting and as a model for protection from wildtype challenge.

We plan to move quickly from this initial demonstration of safety and immunogenicity in a controlled inpatient setting to larger Phase 2/3 program in conjunction with our partners at Serum Institute of India who are currently scaling up manufacturing to support rapid acceleration of our joint development program."

For further information please contact


Open Orphan plc [phone]
Cathal Friel, Executive Chairman

Arden Partners plc (Nominated Adviser and [phone]
Joint Broker) 5900
John Llewellyn-Lloyd / Benjamin Cryer /
Dan Gee-Summons

[phone]
finnCap plc (Joint Broker) 500
Geoff Nash / James Thompson/ Richard Chambers

Davy (Euronext Growth Adviser and Joint
Broker) [phone]
Anthony Farrell

[phone]
Camarco (Financial PR) 4980
Tom Huddart / Hugo Liddy

[jeanesy] 01/12/2020 20:28

Whopping great 710k trade reported late. Interesting

[m5] 01/12/2020 16:15

Guys it was just that screenshot that was posted. Nothing out of the ordinary just that watch this space comment. I know Doc and he usually has a reason for posting such things. We know that news is imminent on a number of fronts, so its not rocket science but his timing is pretty on the money.

Another consolidation day but the longer and tighter we go, the bigger the move, not all of the time, but a lot of the time. DYOR.

[owenski] 01/12/2020 15:38

m5, do you have a link for that

[discojames] 01/12/2020 14:53

Whats the tweet, can you screenshot it?

[m5] 01/12/2020 13:38

Yours is better mate!! ;-)

[trader_3] 01/12/2020 13:32

'A picture is worth a thousand words' - ORPH



Sum's it all up, in my opinion!

[m5] 01/12/2020 13:30

I will, thank you.

Doc is pretty on the money with his posts, knows CF and has his ears to the ground. Most of them I don't give the time of day to but I do take notice of Doc. No advice intended, just an observation.

@DDS_DocHoliday
·
20m
#ORPH Absolutely belting observation from HViVo
@OpenOrphan
#COVID19 #vaccine21 Stay tuned.

[bramble13] 01/12/2020 12:49

M5 ok then ,look at this on MWE..it ticks all the boxes. More your cup of tea,..wonderful potential

[m5] 01/12/2020 12:33

Looks a very nice business. Probably not for me just in terms of share price Most of my stuff that I buy is below 200m mc. It's just the way I work. Chart is a beauty and whilst it has had a good run its not over extended. As you say broken out today, so looks good.

[bramble13] 01/12/2020 11:40

M5 Have you had a look at ERGO yet..what do you think.Just broken out to a good upward trend in tandem with ORPH.

[pierre oreilly] 01/12/2020 10:35

Seems to have stagnated recently - probably healthy after the great rises since c took over. The thing is as i see it, we are pregnant with news on several fronts, and they all seem like mega news to me, which will instantly drive orph beyond the recent 32p high (still be massively undervalued there imo).

If nothing happens, this is worst case, then as time passes, the challenge study business will gradually plod on raking in the tens of millions (40/50m already signed iirc) and for the most conservative investors, the next results will show the profitability of this core business. So with no more news at all, the future share price will rise a lot as the cor business does its stuff - it's all signed, fully booked, for 18m. That alone is pretty unbelievable.

The developments on top of that core are transformative, i.e. big enough to completely revalue orph. An announcement on the wearables (the world's richest men approached orph about their data), or an announcement on the imutexplus float/sale will have an instant major price effect. Another less discussed positive price angle is an rns saying an inst has passed 3% on their own book. I would really rate that as a major price driver over the coming year. If/when c gets the use of another suitable clinic, then for 24 beds, i think you can add another 30m profit to the bottom line. It would instantly be filled with challenge studies - the only problem with the demand is satisfying it.

M, agree - orph is hard to give your real views on because it all sounds so ramplike!. But if posts act as a catalyst for others to look into the 'ramps' then it's worth it.